# Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

> **NCT03382574** · EARLY_PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** Denosumab
- **PROCEDURE:** Salpingo-Oophorectomy

## Key facts

- **NCT ID:** NCT03382574
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-14
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382574, "Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03382574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*